Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …

Cellular perturbations underlying Alzheimer's disease (AD) are primarily studied in human
postmortem samples and model organisms. Here, we generated a single-nucleus atlas from …

The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ 42), total
Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau 181) have proven diagnostic …

Background Alzheimer's disease biomarkers are important for early diagnosis in routine
clinical practice and research. Three core CSF biomarkers for the diagnosis of Alzheimer's …

Abstract Alzheimer's disease (AD), being the number one in terms of dementia burden, is an
insidious age-related neurodegenerative disease and is presently considered a global …

In the past 8 years, both the International Working Group (IWG) and the US National Institute
on Aging–Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's …

Alzheimer disease (AD) originally meant a disorder of early-onset (EOAD;< 65 years of age)
and did not include older patients with “senile dementia.” In fact, the first patient reported …

Alzheimer disease (AD) is biologically defined by the presence of β-amyloid-containing
plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic …

The aggregation of fibrils of hyperphosphorylated and C-terminally truncated microtubule-
associated tau protein characterizes 80% of all dementia disorders, the most common …